Articles tagged with Cancer Medication
Experts say state regulations targeting indoor tanning could drive national policies to reduce skin cancer cases and associated costs. The US Food and Drug Administration has implemented class II device rules for tanning machines, but critics argue these standards are insufficient.
Researchers at the University of Michigan have identified the genetic blueprint of a bacteria that produces ET-743, a compound extracted from a marine invertebrate. This discovery expands understanding of the microbe and could lead to lab-grown production of the cancer-fighting drug.
A new study found that cancer patients' attitudes and beliefs about complementary and alternative medicine are key predictors of its use. Researchers identified specific factors such as expectation of therapeutic benefits, cost concerns, and physician opinions, which varied by sex, race, and education level.
A genetically engineered herpes virus has been shown to halt the progression of skin cancer by killing cancer cells and sparking an immune system response against tumours. The trial involved 436 patients and showed a durable treatment response in 16.3% of patients, with responses extending past three years.
Researchers at the University of Pittsburgh School of Medicine have identified two new classes of RNAs associated with breast cancer biomarker YB-1, which may play a role in prostate cancer progression. The discovery could lead to the development of new cancer treatments and provide insights into human biology.
A new gene subgroup has been identified as a key driver of prostate cancer, allowing for the development of personalized treatment options. The study found that half of all prostate cancer patients have mutations in either C-MYC or L-MYC genes, which can influence disease aggression and treatment response.
Dana-Farber Cancer Institute scientists have developed a new, potent form of targeted cancer therapy using tumor cells' own protein-chopping machinery. The approach causes cancer cells to die quickly, potentially preventing resistance to conventional targeted therapies.
A large international study found that approximately 90% of cases with advanced prostate cancer harbor clinically actionable genetic anomalies. The researchers sequenced DNA and RNA from tumor biopsy samples to identify potential treatments, shedding light on this aggressive type of cancer.
A comprehensive map of genetic mutations in advanced prostate cancers has been created, revealing that nearly 90% of patients have actionable mutations. This breakthrough could lead to targeted treatments and improve patient outcomes.
A recent study has identified genetic abnormalities in prostate cancer that can be targeted with existing or potential drugs, providing a new approach to treatment. The research found that nearly all tumors had at least one genetic aberration, including mutations in the androgen receptor gene.
The Wistar Institute has secured a $5.6 million grant renewal from the Wellcome Trust to further develop cancer drugs targeting Epstein-Barr virus (EBV). The goal is to create a therapeutic that can treat EBV-related cancers by attacking the virus as it remains dormant in patient cells.
A traditional Chinese medicine herbal mixture called Ren Shen Yangrong Tang (RSYRT) significantly reduced fatigue in cancer patients with moderate to severe symptoms. In a Phase I/II trial, RSYRT was found to be safe and effective in improving Qi deficiency, a key factor contributing to fatigue.
Researchers have designed a nanoparticle-based therapy that effectively treats mice with multiple myeloma, a cancer of immune cells in the bone marrow. The nanoparticles carry a Myc inhibitor, which blocks a protein active in many types of cancer, and increase survival by 23 days compared to control groups.
Researchers at University Hospitals Cleveland Medical Center found a new non-invasive stool DNA testing method comparable to colonoscopy for detecting large polyps in African Americans. The study suggests this technology may improve colon cancer screening rates and decrease mortality.
A study has quantified the different mutational profiles of cancer cells in individual tumors, revealing a high degree of variability within one tumor. The researchers found that certain genes behave differently in cancer cells, with some tumors composed of multiple groups with distinct molecular alterations.
Researchers at Oregon State University have developed pactamycin analogs that can cause rapid cell aging and induce premature senescence in cancer cells, slowing or stopping tumor growth. The findings show promise for a new approach to cancer treatment with reduced toxicity and debilitating side effects.
A study published in Annals of Internal Medicine suggests that women with extremely dense breasts do not necessarily need additional imaging after a normal mammogram. However, those with high-risk dense breasts should discuss supplemental screening strategies with their doctors. The American College of Physicians advises 'smarter' canc...
Researchers at the University of Birmingham have found a combination of a cholesterol-lowering drug and a contraceptive steroid to be effective in treating various cancers. The treatment, known as BaP, blocks an enzyme crucial to cancer cell growth and has shown promising results in early stage clinical trials.
Researchers at Cold Spring Harbor Laboratory have discovered the mechanism of action for BRD4, a protein critical to AML cell survival. Disrupting this pathway may lead to improved therapeutic strategies and new molecular targets for treating various cancers.
Researchers at Sandia National Laboratories and the University of Maryland have developed a new cancer treatment method that withholds an essential nutrient from cancer cells, starving them until they self-destruct. The method involves removing asparagine, a nutrient that cancer cells can't produce on their own.
A large study by Boston University School of Medicine researchers found no evidence of an association between Post Traumatic Stress Disorder (PTSD) and cancer incidence. This contradicts plausible theories suggesting a link between stress and cancer, but is consistent with previous population-based studies.
A drug developed in the late 1950s and abandoned due to toxicity has been revived as a treatment for advanced colorectal cancer. The drug, TAS-102, extended patients' overall survival and delayed disease progression with minimal side effects.
A Dartmouth team developed a novel approach for near infrared optical measurements of resected breast tissue using molecular dyes used for surgical specimen margin orientation. This method allows for intraoperative assessment during breast conserving surgery and avoids follow-up resections.
Researchers developed a unique approach using microscopic gas bubbles to deliver directly to cancer cells a viral gene therapy in combination with an experimental drug. The treatment strategy used a novel 'cancer terminator virus' and demonstrated enhanced prostate cancer cell death while sparing healthy cells in preclinical experiments.
Scientists at CSHL have developed a method to comprehensively identify binding pockets inside cancer cells that can be targeted by drugs. Using CRISPR, they surveyed about 200 potential targets and identified six known targets and 19 new ones in leukemia cells.
Researchers at Karolinska Institutet have discovered how cancer cells can infiltrate the lymphatic system by mimicking immune cells. This finding may lead to the development of new treatments targeting metastasis via the lymphatic system.
A study published in the Journal of Cell Biology suggests that new understanding of cell division can reveal potential targets for cancer therapy. Researchers have identified key steps in cell division and highlighted novel targets that could be inhibited to block cancer cell division.
Researchers developed a combinatorial approach to treating glioblastoma by combining three classes of anti-cancer drugs. The study found that a combination of EGFR inhibitor, PLK1 inhibitor and DNA-damaging agent effectively halted tumor growth in mouse models and human glioblastoma tissue.
Researchers used organoids derived from human tumor samples to test cancer drugs and predict patient response. The findings demonstrate the power of organoids to capture complex mutations in tumours.
Researchers grew 22 organoids from tumor tissue of 20 patients with colorectal cancer and found they closely replicate key properties of the original tumors. These cultures can be used to predict drug sensitivity and pave the way for personalized treatment approaches.
A phase I clinical trial has begun for a new 'resistance-busting' experimental skin cancer drug, administered to the first patient just three months after a major publication described its potential. The trial aims to establish the safe maximum dose for a planned phase II clinical trial, focusing on advanced melanoma patients.
Researchers have found a possible treatment for diffuse intrinsic pontine gliomas (DIPG), a lethal form of pediatric brain cancer. Panobinostat, an epigenetic drug, may slow DIPG growth and extend survival rates in patients.
Researchers at Dana-Farber Cancer Institute identified three types of resistance to a new lung cancer drug, highlighting the need for combination therapies and novel strategies to overcome resistance mechanisms.
A study by researchers at the University of Cincinnati has found that generic formulations of tacrolimus are bioequivalent to the name-brand version, suggesting they can be used interchangeably post-transplant. The findings have important implications for immunosuppressant drug management and patient care.
Researchers found that teens aged 15-17 who mixed energy drinks with alcohol were four times more likely to meet the criteria for alcohol use disorder. The study highlights the potential risks of combining these substances, particularly among adolescents.
A new targeted therapy drug rociletinib demonstrates significant activity against treatment-resistant EGFR-mutant lung tumors, improving outcomes for patients with advanced tumors. The drug showed promising results in patients with T790M-driven resistance, resulting in tumor shrinkage and symptom relief.
The pharmaceutical industry's regulatory system is criticized for lacking accountability and being evidence-based, resulting in high NHS costs and inefficient use of technology appraisal work. The Cancer Drugs Fund is also singled out for criticism due to its inequitable allocation of funds and discrimination against other diseases.
A phase 1/2 trial of rociletinib in EGFR-mutant non-small cell lung cancer showed a 59% response rate and 13.1 month progression-free survival, offering hope for patients with previously treated disease.
Chemists have designed four new atomic arrangements of gold nanoparticle clusters, exhibiting lower potential energy and greater stability than previous configurations. The arrangements could inform the use of these nanoparticles in transporting pharmaceutical drugs and removing pollutants from industrial byproducts.
A Mayo Clinic-led research team has identified a molecular switch in the HER2 protein that sets off a cascade of events leading to cancer. Disrupting this site can stem the growth of breast cancer cells more effectively than current treatments.
Scientists have identified 35 genes and three long intervening noncoding RNA molecules that spur aggressive activity in HER2+ breast cancer. These findings provide a new target for treatment approaches, potentially leading to RNA-based therapeutics.
Researchers identified specific molecular profiles and mutational patterns that can help determine which hepatocellular carcinoma patients benefit from targeted anticancer treatments. The study suggests that exome sequencing can be used to identify potential new targets for therapy, leading to optimized personalized patient care.
A Case Western Reserve University researcher has won a $500,000 NSF CAREER grant to develop tiny sensors capable of detecting insecticides in Lake Erie or determining subtypes of human cancers. The technology combines antibodies with plant viruses to create a large surface area for targeting pollutants or cancer cells.
A patented technology called CIVO enables simultaneous testing of multiple cancer drugs in a patient's tumor, accurately predicting systemic response. This innovation has shown positive findings using multiple cancer drugs tested in xenografted mouse models and canine patients.
A new implantable device can carry small doses of multiple drugs to treat cancer, allowing researchers to measure their effectiveness in a tumor. The device was tested on mice with human prostate, breast, and melanoma tumors, showing promise in identifying the most effective treatment for each patient.
Researchers found that a toxic mushroom-based drug can suppress the POLR2A gene in cancer cells, resulting in complete tumor regression and reduced toxicity. The study's findings provide a new therapeutic approach for human cancers with common genomic alterations.
A Purdue University study reveals that cancer drug decitabine combats cell damage by taking the place of nucleotide cytosine, restoring 'meaning' to garbled gene messages. An uptick in 5-hydroxymethylcytosine levels could indicate cancer treatment success.
A major trial has shown that olaparib can effectively treat advanced prostate cancer in men with defects in DNA repair genes. The results suggest that up to 30% of patients with terminal prostate cancer may benefit from the drug, which could become a treatment option if replication is confirmed in further trials.
Researchers have tested an experimental immune system drug, MPDL3280A, in a preliminary human study and found it to be generally safe and well-tolerated. The therapy aims to restore the immune system's ability to recognize and attack cancer cells, with promising results in controlling disease in some patients.
Researchers have identified a new mechanism linking chronic inflammation to cancer progression, revealing the role of MUC1 and p65 in driving pro-inflammatory cytokine gene expression. This discovery offers potential therapeutic targets for developing drugs that can interrupt the cancer-inflammation process.
A new report from UC San Diego highlights the scope of the problem, finding that only 1,510 counterfeit incidents were reported between 2009 and 2011, despite an estimated 100,000-1 million deaths per year. The study calls for improved detection, data collection, and analysis to combat falsified medicines.
A gene expression model called COXEN predicts canine osteosarcoma response to doxorubicin, potentially allowing veterinary oncologists to choose the most effective drug. The approach validates human models used to predict drug response in clinical trials.
A new study from the University of Pennsylvania School of Medicine found that pembrolizumab, a PD-1 inhibitor, shrank or stabilized tumors in most patients with pleural mesothelioma. The medication was safe and showed promise for treating this rare and deadly form of cancer.
Researchers at MD Anderson Cancer Center identified three subsets of lung cancer with KRAS gene mutations, each with unique signaling patterns and susceptibility to different therapeutic strategies. These subsets may offer new approaches for treating lung adenocarcinoma, the most common form of lung cancer.
Researchers at Saint Louis University discovered that targeting the A3 adenosine receptor can 'turn off' pain signals in the spinal cord, providing potential relief for patients with chronic pain. The study found that activating this receptor promotes GABA signaling, which is often lost or diminished in chronic pain conditions.
A common anti-fungal drug, itraconazole, has shown potential in treating metastatic prostate cancer and non-small cell lung cancer. The ReDO project is exploring its use in various cancers, offering a more affordable alternative to existing treatments.
A new clinical trial found that early initiation of palliative care significantly improved one-year survival rates among patients with late-stage cancer. Additionally, caregivers experienced reduced depression and stress levels when interventions started earlier in the patient's life.
A multicenter clinical trial launched by Yale University aims to evaluate the effectiveness of personalized medicine in treating metastatic melanoma. The trial will enroll patients lacking a particular genetic mutation and use molecular sequencing techniques to match targeted drugs to unique genetic alterations.
A recent study published in Science Translational Medicine found that many genetic alterations identified using tumor-only sequencing are not associated with cancer, but rather reflect inherited germline mutations. The study analyzed DNA from 815 patients and found that nearly half of the detected genetic alterations were 'false positi...
Dartmouth researchers have identified a specific temperature that stimulates an antitumor immune response, which resists metastatic disease. Using iron nanoparticles and alternating magnetic fields, they found that temperatures of 43 degrees centigrade trigger the systemic immune response.